ArticlePublic health genomics2012
HER2 evaluation and its impact on breast cancer treatment decisions.
Article in Public health genomics, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 2 syntheses or guidelines pooled it, 61 citations in OpenAlex.
- Health-related quality of life in Her2-positive early breast cancer woman using trastuzumab: A systematic review and meta-analysis.Frontiers in pharmacology · 2023Pooled it
- Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update.Archives of pathology & laboratory medicine · 2014Guideline
- Article
- DeSpaST: deconvoluting spatial transcriptomics signals to cell-level resolution using histology images.Briefings in bioinformatics · 2026Article
- Article
- Review
- Kazakhstani HER2 breast cancer digital image dataset: The ADEL dataset.Data in brief · 2025Article
- BlurryScope enables compact, cost-effective scanning microscopy for HER2 scoring using deep learning on blurry images.NPJ digital medicine · 2025Article
- Scalable Nuclei Detection in HER2-SISH Whole Slide Images via Fine-Tuned Stardist with Expert-Annotated Regions of Interest.Diagnostics (Basel, Switzerland) · 2025Article
- Utility of Axillary Staging in Older Patients with HER2-Positive Breast Cancer.Annals of surgical oncology · 2024Article
- Predicting HER2 Status Associated with Breast Cancer Aggressiveness Using Four Machine Learning Models.Asian Pacific journal of cancer prevention : APJCP · 2024Article
- Development and Validation of a Prognostic Nomogram Model for HER2-Positive Male Breast Cancer Patients.Asian Pacific journal of cancer prevention : APJCP · 2024Article
- The Performance and Clinical Applicability of HER2 Digital Image Analysis in Breast Cancer: A Systematic Review.Cancers · 2024Review
- Intracranial management of HER-2 overexpression breast cancer with extensive volume or symptomatic brain metastases.Frontiers in oncology · 2024Article
- Automated HER2 Scoring in Breast Cancer Images Using Deep Learning and Pyramid Sampling.BME frontiers · 2024Article
- Causal relationships between serum matrix metalloproteinases and estrogen receptor-negative breast cancer: a bidirectional mendelian randomization study.Scientific reports · 2023Article
- HER2 classification in breast cancer cells: A new explainable machine learning application for immunohistochemistry.Oncology letters · 2023Article
- CT Findings From Interstitial Lung Diseases in Patients With Metastatic Breast Cancer Treated With Fam-Trastuzumab Deruxtecan: A Single Institutional Experience.Journal of breast cancer · 2022Article
- Prognostic factors of brain metastasis and survival among HER2-positive metastatic breast cancer patients: a systematic literature review.BMC cancer · 2021Review
- Texture Analysis Using Semiquantitative Kinetic Parameter Maps from DCE-MRI: Preoperative Prediction of HER2 Status in Breast Cancer.Frontiers in oncology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
Abstract
backgroundEighteen to twenty percent of breast cancer tumors show abnormal amplification of the Human Epidermal growth factor Receptor 2 (HER2) gene and increased expression of the associated protein. HER2 amplification is associated with rapid tumor proliferation and shorter disease-free and overall survival. Because women with HER2 amplification are more likely to benefit from treatment with the drug trastuzumab, testing for HER2 is recommended to guide therapy. However, little is known about use of HER2 testing in real-world settings. This study examined uptake, use, appropriateness of HER2 testing, and the relationship between HER2 test results and treatment decisions.
methodsWe assessed electronic data from 3,634 patients with invasive breast cancer diagnosed from 1998 to 2007 in a large integrated health system. We collected data on patient and tumor characteristics, HER2 testing status, test results, and trastuzumab treatment.
resultsFrom 1998 to 2000, the percent of patients who underwent HER2 evaluation increased from 12 to 94%; <3% of women with ductal carcinoma in situ, for whom HER2 testing is not recommended, were tested. Trastuzumab use increased 5-fold after 2004, when guidelines expanded to include recommending adjuvant treatment for early-stage breast cancer in addition to metastatic treatment. Ninety-five percent of women receiving trastuzumab had a positive HER2 result. After 2004, 55% of women with invasive breast cancer and overexpression of HER2 received trastuzumab treatment; this ranged from 44% of women with localized breast cancer to 80% of women with distant metastatic disease.
conclusionsThese findings illustrate appropriate and effective implementation of a HER2 testing strategy in a managed care setting.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.